Abstract

“CLINICAL EVALUATION OF STANDARDIZED FENUGREEK SEED EXTRACT AS FUROSTENOLIC SAPONINS (FUROCYST) IN POLYCYSTIC OVARY SYNDOME PATIENTS.”

Amrita Sarkari Jaipuriar, Sushil Kumar Gupta, Pawan K Goel, Gopesh Lamgora*

Abstract

Background: Polycystic Ovarian Syndrome (PCOS) is one of the most common endocrine conditions affecting women of reproductive age Group with prevalence of approximately 7-10% worldwide. Objective: The objectives of the study were to find out the effect of Standardized Fenugreek Seed extract as Furostenolic Saponins (FUROCYST) on reduction in ovarian volume and the number of ovarian cysts. Method: An open labeled, Multicentric, single-arm and non-comparative study was planned on 50 female patients suffering from PCOS. Patients were enrolled as per inclusion i.e. Premenopausal women between 18-45 years of age, BMI less than 42, diagnosed with PCOS, with adequate hepatic, renal and haematological functions. Patients willing to give informed consent in writing Patients with Hysterectomy/Congenital adrenal Hyperplasia/Cushing's Syndrome/Androgen secreting tumour/ Thyroid-dysfunction/ Hypo-gonadism were excluded. Women were allocated to receive Furocyst and were assesed on parameters of USG & hormonal on second day of cycle before and every 4 weeks within treatment period of 12 weeks Result: After treatment for 3 months with Furocyst caused significant reduction in ovary Volume (p 0.000), 46% of study population showed reduction in cyst size who had bigger cyst, 36% study population showed complete dissolution of cyst who had small cyst, 12% study population got pregnent and 71% patients reported regular menstrual cycle on completion of treatment and LH: FSH ratio was also reduced to normal. Overall 94% of patients reported positively or got benefitted from Standarized Fenugreek seed extract (FUROCYST) dosing. No changes were observed in LFT, KFT and Haemogram level. Conclusions: Present Study indicates that Standardized Fenugreek seed extract as Furostenolic Saponins (FUROCYST) is very effective and safe in the management of Poly Cystic Ovary Syndrome in women of reproductive age Group.

Keywords: .